On September 16, Caris Life Sciences, Inc. rose 5.82% in regular trading, trading at $27.60 per share, with turnover of approximately $85.19 million. The rally was driven by a combination of UBS initiating coverage and continued positive sentiment following robust quarterly results.

UBS recently initiated coverage on Caris Life Sciences, Inc. with a Neutral rating and a $28 price target. Analysts polled by FactSet assign the stock an average Overweight rating with a mean target price of $27.08. The initiation adds to a growing wall of institutional coverage, following earlier initiations from Goldman Sachs, Jefferies, and Piper Sandler.

Fundamentally, the company reported Q2 revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million. This follows Q1 revenue of $216.2 million, representing 79% year-over-year growth, with EPS reaching breakeven versus an expected loss. The company also reaffirmed full-year revenue guidance of $1.0 billion to $1.02 billion. On the product front, the company has continued to expand its precision oncology portfolio with launches including PTEN IHC testing for metastatic prostate cancer and ChromoSeq for myeloid malignancies, reinforcing its growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)